When a strategic investor writes a cheque, the share percentage is the easy part to remember. The harder part may be a clause telling you whom to call when somebody else wants to buy the company. Personalis received about $50 million from Merck in December 2024. In return, Merck received shares and a contractual route into a future sale process. Less than two years later, Personalis agreed to be acquired by Tempus, an existing commercial partner and shareholder. Merck did not bid. It signed a separate agreement to support Tempus's deal.M1M2M3
The useful question for a founder is what the original investor right actually did. The December 2024 agreement did not promise Merck first refusal, a right to match an offer, or approval over the winning buyer. It promised information and a chance to compete. Comparing that clause with the later sale chronology and voting agreement shows three distinct positions: Merck could hear about a process, choose whether to bid, and later choose whether to commit its stock to someone else's transaction. A founder who calls all three “strategic support” loses track of when leverage changes hands.M1M2M3
The investment bought early notice, with limits
Personalis issued Merck 14,044,943 shares at $3.56 each on December 19, 2024, for just under $50 million. The filing said $10 million of the proceeds would be reserved for an ISO-certified laboratory outside the United States, in a region agreed with Merck. The investment therefore had a commercial purpose as well as a financing purpose. Its sale provisions deserve to be read in that context: Personalis was bringing a major industry participant onto the cap table while preserving room to seek other buyers.M1M5
Section 4.4 of the investment agreement identifies two triggers. One is a bona fide third-party proposal for a change of control that the board has not decided to leave alone. The other is the board starting a process to solicit offers. In either case, Personalis generally had to give Merck written notice within two business days. It did not have to identify the other party or disclose the terms of that party's offer. It did have to say whether a written offer or a process existed, identify the transaction type and provide the proposed timeline. Material changes to the notice information generally required a supplement within three business days.M1
Merck then had a reasonable opportunity to respond or join the sale process on substantially the same footing as other participants. If it wanted to take part, Personalis had to answer reasonable questions and provide reasonably requested diligence material and management access on customary terms. The board could withhold notice if, after consulting outside counsel, it determined in good faith that giving it would conflict with directors' fiduciary duties. The right also lasted only while Merck and affiliates held at least half of the shares bought at closing, with the agreement's adjustment rules.M1
This is the contractual detail hidden inside “strategic relationship.” The phrase sounds as if two executives should book coffee. Section 4.4 made the M&A team book a calendar reminder, draft a notice and prepare to let the investor into diligence. That can improve price discovery when the investor is a credible buyer. It also makes confidentiality, timing and competitive information questions part of a financing round, even before anyone has hired a sale adviser. The agreement's carve-outs show that Personalis tried to retain board discretion rather than give Merck an automatic look at every stray approach.M1
There was a matching restraint on Merck. The agreement's standstill generally restricted it from seeking a public takeover or trying to influence the board without consent for up to two years, subject to its terms. Merck could still submit a confidential negotiated proposal. Its separate board-recommendation voting commitment covered specified matters such as director nominations and compensation; the agreement expressly left Merck free to vote in its own discretion on a shareholder vote for a change of control. The December investment thus created an opportunity to join a sale, while stopping short of a pre-signed vote for any future buyer.M1
If you are taking a strategic investment, ask counsel to mark the trigger for notice. Does it cover only a signed offer, a serious indication, an adviser-run process, or a sale of key intellectual property? Then mark what the investor learns, when it learns it, what it may inspect, and when the board may hold back. Those verbs will decide how much freedom you have when the buyer you did not expect calls.
The process had another strategic holder at the table
Tempus already sold and marketed Personalis's cancer monitoring test under a commercial arrangement. In August 2024, it bought additional Personalis shares and exercised warrants, giving Personalis roughly $36 million of gross proceeds in total. The merger proxy says Tempus then held about 19.3% of Personalis and received additional protections in connection with a sale to a Tempus competitor. Its commercial agreement also contained a standstill that limited its ability to make a proposal requiring public disclosure without Personalis board approval.M2
That set up an unusual auction. Merck had a right to notice and a comparable chance to participate. Tempus knew the company as a commercial partner and already owned a material stake, yet needed a board waiver for a public proposal. Other potential acquirers could enter, but some were competitors who would need sensitive information and regulatory commitments. These facts do not prove the outcome was fixed. They show why a founder should map commercial contracts alongside the cap table before describing a sale as open or closed.M1M2
The proxy chronology resists a simple story about an insider buying a company without a contest. Personalis had received interest from another company, called Party A, in 2024. In 2026, its board and advisers advanced talks with Tempus, Party A and a second potential bidder, Party B. By the June 30 board meeting, advisers reported that Merck was not interested in acquiring Personalis. Party B later declined to bid because it could not offer a meaningful premium to the trading price. Party A continued to negotiate and eventually indicated $17 per share in stock. Tempus's final proposal was $16.25 per share, primarily in Tempus stock with an option for Tempus to fund up to half the consideration in cash.M2M4
The $17 figure is the strongest challenge to the board's choice. The proxy describes why directors preferred Tempus's lower headline value: they judged Party A's antitrust risk, its requested waiver of a third party's change-of-control provision and the delay to signing or closing to reduce the value shareholders could actually expect. That is the board's assessment, disclosed in its proxy, rather than a proven market value for Party A's stock or a regulator's finding. The other bidder's higher number deserves to remain visible. The proxy says Party A stopped substantive engagement after saying its own board would not approve more than $17 and asking for more time.M2
Personalis did not simply hand Tempus every term it requested. The proxy says it rejected Tempus's proposed amendments to the commercialization agreement and a phased acquisition structure. The board authorized a standstill waiver on July 18, and counsel delivered it on July 19 after negotiating price and legal terms. That chronology matters because a pre-existing strategic position can create advantages without making a board powerless. A founder needs to know which rights bind the company and which decisions the board can still make at the negotiating table.M2
There is a fair rival reading here. Tempus may have been the best available buyer because it knew the product, could close sooner and offered a stronger route through regulatory review. Independent reporting noted that shares of both companies fell after announcement and quoted analyst skepticism about the stock-based consideration. That reaction does not decide whether Personalis selected the right buyer; it does warn against treating “$16.25” as cash already in an investor's account. The announced merger still depended on a shareholder vote and other closing conditions when the definitive proxy was issued.M2M4
A chance to bid became a separate voting commitment
Merck's 2024 sale-process clause did not tell it how to vote on a Tempus transaction. The July 20, 2026 voting agreement did. In it, Merck promised to vote the Personalis shares it controlled for the merger agreement and against competing acquisition proposals or actions expected to impede the deal. That promise ends if the merger takes effect, the merger agreement validly ends, or specified adverse changes to the deal occur. It was signed at the same time as the merger agreement, after Merck had declined to pursue an acquisition itself.M1M2M3
The buyer's shares were committed too. The proxy says Tempus held about 12% and Merck held about 13% of Personalis voting power when the merger was signed. Approval requires a majority of all outstanding Personalis shares, not merely a majority of votes cast at the meeting. On the October 15 record date there were 108,387,392 shares outstanding. The proxy calculates that, if Tempus and Merck vote all their shares yes, another 27,109,687 shares must vote yes for the deal to pass.M2
Put the denominator where shareholders can see it. The proxy lists 14,044,943 shares for Merck and 13,039,067 for Tempus. Together they account for 27,084,010 shares, almost exactly one-quarter of those outstanding. The remaining pool is 81,303,382 shares. The proxy's 27,109,687 required outside yes votes equal 33.34% of that pool, using those disclosed holdings. This is a calculation about the stated voting structure, not a prediction that the remaining holders will vote that way. It is also different from requiring a majority of the unaffiliated shares to approve the deal as a separate condition.M2M3
The sequence is the original lesson of the documents. In 2024, Merck bought a contractual route into a sale process and reserved its own judgment on a change-of-control vote. In 2026, it declined to bid, then used that judgment to bind its shares to the Tempus transaction. Those are three separate decisions made under two agreements. Treating the initial notice right as a secret veto would exaggerate it; ignoring the later support agreement would understate the voting head start available to the buyer.M1M2M3
Read a strategic cheque as a future process document
Before signing with an industry investor, make a one-page rights map across the investment agreement, commercial contract and any shareholder agreement. Put the company's next possible sale in the first column. For each contract, identify who gets notice, who gets information, who may bid, who can block or delay a third-party transaction, and who must vote. Record the trigger, deadline, duration, ownership threshold, exceptions and board waiver for each right. A standstill and a sale notification clause may appear in the same agreement while pulling in opposite directions.
Then test a rival bidder. If it is a competitor of the strategic investor, what commercial terms change on a sale? Can diligence be given to both bidders without exposing sensitive customer or product data? Can the board decline to pursue a weak approach without notifying every strategic holder? If a bidder demands a pre-signing vote commitment from another large holder, calculate the remaining approval hurdle using outstanding shares and the actual proposed vote condition. The vote math in a related insider bid shows why “majority” is incomplete until you name the voters and denominator.
The tradeoff is real. Personalis received financing and commercial support from two major industry participants; a standalone path, its board said, would require substantial additional capital. The same relationships created sale-process rights, existing ownership positions and contract questions that had to be handled when a buyer emerged.M2M5 Merck's notice right did not stop another bidder from indicating a higher nominal price. The board's account says it chose the lower nominal offer after weighing the other bid's closing risks. Personalis's November 4 quarterly filing still described a pending merger and a November 30 shareholder vote. That vote will test whether shareholders accept the board's judgment.M2M6
If a strategic investor asks for a “reasonable opportunity” in your next financing, ask your deal lawyer to translate that phrase into a mock sale calendar before the wire arrives. Personalis's documents show why the calendar, the bidding rules and the eventual voting agreement must each have their own box.